Skip to main content

Call for Expressions of Interest MSCA-PF 2022: Cellular Immunotherapy and Oncohematology

Maimonides Biomedical Research Institute of Cordoba - IMIBIC The Human Resources Strategy for Researchers
15 Feb 2022

Hosting Information

Offer Deadline
EU Research Framework Programme


Organisation / Company
Maimonides Biomedical Research Institute of Cordoba - IMIBIC
GC14 Cellular Therapy
Is the Hosting related to staff position within a Research Infrastructure?

Contact Information

Organisation / Company Type
Private with public mission
Postal Code
Avda. Menéndez Pidal s/n


Dr. Inmaculada Concepción Herrera Arroyo (ORCID: 0000-0003-0055-2270) welcomes Expressions of Interest from researchers of any nationality, with a maximum of 8 years of postdoctoral experience, excellent scientific track record, and international experience, to submit an application with her for the MSCA PF call, which closes on the 14 of September 2022.

Interested researchers should contact us via email by 30 of April.

Please include “MSCA 2022” in the subject field and attach your CV.



Our group focuses on clinical and translational research in advanced therapies, specifically in cell therapy and cell-gene therapy. We have extensive experience in independent clinical trials of cell therapy from cells derived from bone marrow in cardiovascular pathology, neurological diseases, and transplant-related diseases (GVHD). Our group is a central unit of cell production under GMP conditions that coordinates its activity with other IMIBIC groups in the development of new Advanced Therapy Medicinal Products (ATMPs) for various pathologies with a high sociosanitary impact.

Our group is currently working in collaboration with the GENYO Cell and Gene Therapy group in Granada on the preclinical development of new allogeneic CAR-T on predefined lymphocyte subpopulations and with inducible CAR expression. We are also about to start a new line of cellular immunotherapy in myeloid neoplasms such as acute myeloblastic leukemia.

We are looking for potential candidates to develop a project proposal in the field of immunotherapy for oncohematological diseases, specifically focussed on CAR-T or CAR-NK.

For more information about our group, please visit



We are looking for motivated candidates with:

  • Experience in preclinical models of CAR-T
  • International experience (e.g. doctoral studies abroad, postdoctoral stays or research visits abroad, participation in international projects)
  • Very good written and spoken level of English
  • Experience in scientific communication activities and intersectoral experience is valued

MSCA PF Eligibility criteria. Eligible candidates must:

  • hold a PhD degree
  • not have more than 8 years of postdoctoral research experience
  • have lived outside Spain for at least 2 years in the past 3 years immediately before the call deadline (14th Sep 2022)

Detailed eligibility rules: tenders/opportunities/portal/screen/opportunities/topic-details/horizon-msca-2022-pf-01-01

For more information about MSCA PF:…



Candidates fulfilling the eligibility and selection criteria, with a good match with the group’s ongoing research, and complementary knowledge and skills, will be invited to write an application for the MSCA PF call. For this, the candidate will receive instructions and full support from the Supervisor and the IMIBIC’s International Project’s Office.

Selected candidates will be informed by early May and proposals developed throughout the spring and summer months. The MSCA call closes on the 14th of September 2022.



The Maimonides Biomedical Research Institute of Cordoba - IMIBIC is a joint biomedical research institute of the Reina Sofia University Hospital and the University of Cordoba. As such, its mission is to promote talent, collaboration, and multidisciplinary international research and innovation, towards solving health problems in a sustainable and socially responsible way.

IMIBIC is one of the 32 research institutes in Spain accredited by the National Institute of Health Carlos III (ISCIII), and awarded by the European Commission with the “HR Excellence in Research” recognition since 2017.

IMIBIC was founded in 2008 and since 2015 operates in the IMIBIC building with new facilities including laboratory spaces for basic and clinical research, several Research Support Services equipped with state of the art technologies (genomics, proteomics, imaging, bioinformatics, technological innovation, animal experimentation, etc.) and dedicated areas to carry out clinical studies. The proximity to the Reina Sofia University Hospital ensures access to patients and ideal conditions to carry out truly translational clinical research.

Career development

MSCA Fellows will have access to IMIBIC’s extensive training agenda, including yearly events, as well as scientific and transversal skills courses organised by the IMIBIC’s Training Unit (ACSA quality accreditation) and external collaborators.

The research groups offer substantial network and opportunities for collaboration at national and international levels, including participation in ongoing EU projects, involvement in activities organised by the different platforms, networks and infrastructures in which IMIBIC or the host group is a member, and participation in EU, national, and regional networking and partnering events.

IMIBIC actively organises public engagement activities and encourages researchers to develop new and innovative ways of reaching the non-scientific audience. The fellows will actively take part in open Lab days, European Researchers’ Night, activities with the healthcare professionals and patients, in line with the institute’s Responsible Research and Innovation (RRI) objectives and activities.

MSCA fellows will develop a Career Development Plan together with their supervisors. In addition to research objectives, this plan comprises the researcher’s training and career needs, including training on transferable skills, teaching, planning for publications and participation in conferences.